Lead Product(s) : OLX75016
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Licensing Agreement
OliX, Lilly Ink Global Deal for MASH & Cardiometabolic Indications
Details : Under the licensing agreement,Lilly will focus on the development and commercialization of OliX’s OLX75016, a Phase 1 candidate primarily targeting metabolic-associated steatohepatitis indications.
Product Name : OLX75016
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
February 10, 2025
Lead Product(s) : OLX75016
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : OLX75016
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
OliX Pharmaceuticals Begins Patient Dosing in Phase 1 Trial of OLX75016 for MASH
Details : OLX75016 It is being developed as a novel treatment approach for metabolic dysfunctions associated with non-alcoholic fatty liver disease linked to obesity.
Product Name : OLX75016
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
February 13, 2024
Lead Product(s) : OLX75016
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DD01
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
D&D Pharmatech Granted Fast Track Designation for DD01 for NASH/MASH Treatment
Details : DD01 is a proprietary, once-weekly dual agonist of GLP-1 (glucagon-like peptide-1) and glucagon receptors. It is being evaluated for the treatment of adults with non-alcoholic steatohepatitis.
Product Name : DD01
Product Type : Peptide
Upfront Cash : Inapplicable
February 04, 2024
Lead Product(s) : DD01
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OLX75016
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The company has received approval from the Alfred Human Research Ethics Committee to conduct a Phase 1 clinical trial of drug candidate OLX75016 for the treatment of non-alcohol steatohepatitis.
Product Name : OLX75016
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
December 22, 2023
Lead Product(s) : OLX75016
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LB-P8
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LB-P6 and LB-P8, targeting autoimmune disease and non-alcoholic steatohepatitis (NASH), respectively. LB-P6 is a candidate substance that is expected to have therapeutic effects on various autoimmune diseases.
Product Name : LB-P8
Product Type : Microorganism
Upfront Cash : Inapplicable
October 28, 2022
Lead Product(s) : LB-P8
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LB-P8
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LISCure's Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD) from US FDA
Details : LB-P8, LISCure's microbiome novel drug, as treatment of PSC. LB-P8 is, to the best of company's knowledge, the first drug to be granted orphan drug designation in the field of microbiome-based treatment for metabolic diseases.
Product Name : LB-P8
Product Type : Microorganism
Upfront Cash : Inapplicable
August 12, 2022
Lead Product(s) : LB-P8
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LG203003
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LG Chem Announces First Subject Enrolled in Phase 1 Clinical Trial of NASH New Drug
Details : LG203003 is second NASH compound is formulated to suppress the accumulation of fat in liver cells by selectively impeding the activation of DGAT2 (diacylglycerol O-acyltransferase 2), a triglyceride synthetase, thus reducing liver cell damage.
Product Name : LG203003
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 14, 2022
Lead Product(s) : LG203003
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : LB-P8
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LB-P6 and LB-P8, targeting autoimmune disease and non-alcoholic steatohepatitis (NASH), respectively. LB-P6 is a candidate substance that is expected to have therapeutic effects on various autoimmune diseases.
Product Name : LB-P8
Product Type : Microorganism
Upfront Cash : Inapplicable
September 30, 2021
Lead Product(s) : LB-P8
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HM15211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hanmi’s anti-NASH drug candidate set to become ‘game changer’ in global pharmaceutical market
Details : Hanmi is planning to begin the global Phase 2 trials of LAPSTriple Agonist in the second quarter this year with biopsy-proven NASH patients.
Product Name : HM15211
Product Type : Peptide
Upfront Cash : Inapplicable
February 28, 2020
Lead Product(s) : HM15211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HM15211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hanmi Pharma to develop innovative drugs for rare diseases
Details : HM12525A is the world's first anti-obesity treatment that works as a once-weekly injection. Its efficacy was proven to be higher than existing daily-injection obesity treatment in Phase 2 trials.
Product Name : HM15211
Product Type : Peptide
Upfront Cash : Inapplicable
January 16, 2020
Lead Product(s) : HM15211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable